Consciousness and Psilocybin Effects on Well-Being: Pilot Phase (CoPE Pilot)

This pilot study aims to establish a dosing regimen for intravenous (IV) psilocybin that will allow the drug to be administered to asleep participants without awakening them and assess whether this dosing regimen produces a psychedelic experience.

Healthy participants (n=15) will be administered 2 mg of psilocybin via IV infusion and left to sleep for 1 hour. If participants’ sleep is disturbed, dosing strategies will be reassessed.

This is the latest trial at the University of Wisconsin-Madison in collaboration with the Usona Institute.

Topic Neuroscience
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Usona Institute
The Usona Institute was founded by Bill Linton and Malynn Utzinger. Currently, 18 people are associated with it. The institute is a non-profit that sponsors psilocybin research (and is funded by sponsors/philanthropists).

University of Wisconsin-Madison
The Transdisciplinary Center for Research in Psychoactive Substances (TCRPS) was launched at the University of Wisconsin-Madison in 2021.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.